Media headlines about Summit Therapeutics PLC (NASDAQ:SMMT) have trended positive this week, Alpha One Sentiment Analysis reports. The research firm, a division of Accern, rates the sentiment of media coverage by reviewing more than 20 million news and blog sources. Alpha One ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Summit Therapeutics PLC earned a daily sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned media headlines about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the company’s share price in the immediate future.
A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Summit Therapeutics PLC from a “buy” rating to a “hold” rating in a report on Saturday, April 1st. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of Summit Therapeutics PLC in a research note on Wednesday, March 22nd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Summit Therapeutics PLC currently has a consensus rating of “Buy” and a consensus target price of $25.00.
Shares of Summit Therapeutics PLC (NASDAQ:SMMT) traded down 2.67% during midday trading on Thursday, reaching $11.32. 9,730 shares of the company’s stock traded hands. Summit Therapeutics PLC has a 52-week low of $5.31 and a 52-week high of $19.75. The company has a 50 day moving average of $12.45 and a 200 day moving average of $11.11. The firm’s market cap is $140.12 million.
ILLEGAL ACTIVITY WARNING: This piece was originally posted by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at http://sleekmoney.com/summit-therapeutics-plc-smmt-receiving-favorable-news-coverage-report-finds/1739442.html.
About Summit Therapeutics PLC
Summit Therapeutics plc is a biopharmaceutical company, which is engaged in drug development. The Company is focused on the discovery, development and commercialization of medicines for indications for which there are no existing or only inadequate therapies. It is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/summit-therapeutics-plc-smmt-receiving-favorable-news-coverage-report-finds/1739442.html
Receive News & Ratings for Summit Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.